COI.
search Request for Consideration arrow_forward menu
close Submit Innovation
close
Healthcare & Life Sciences verified Verified Outcome TRL 8

AI Drug Design (Small Molecule)

domain Client: A top global pharmaceutical company handshake Provider: Exscientia schedule Deploy: 2022
85 Impact
Enterprise Ready
Evidence Score: B/10
Strength: Medium

Executive Summary

ANALYST: COI RESEARCH

Partnership to use AI-driven design to accelerate the discovery of small molecule drug candidates for oncology and immunology.

rate_review Analyst Verdict

"Medium Risk (Scientific). AI drug discovery is still proving its 'end-to-end' value (FDA approval), but the speed in the 'hit-to-lead' phase is undeniably faster than traditional methods."

lock
Full Audit Report Available Includes Risk Register, Technical Specs & Compliance Data.

warning The Challenge

Traditional drug discovery is a slow, stochastic process of trial and error. Identifying a viable candidate typically takes 4-5 years before clinical trials can begin.

psychology The Solution

Leveraged Exscientia's AI platform to design molecules. The AI balances potency, selectivity, and pharmacokinetics simultaneously, designing compounds that are more likely to succeed.

settings_suggest Technical & Deployment Specs

Integrations
Lab Automation
Deployment Model
SaaS / Partnership
Data Classification
IP / Molecular Data
Estimated TCO / ROI
High (Deal value)
POC Summary ( to )

"N/A"

shield Risk Register & Mitigation

Risk Factor Severity Mitigation Strategy
Clinical Failure High Diversified pipeline

trending_up Impact Trajectory

Audited value realization curve

Accelerated 'hit-to-lead' timeline Verified Outcome
Primary KPI$100M upfront investment validation
Audit CycleCandidate entered clinical trials

policy Compliance & Gov

  • Standards: GxP
  • Maturity (TRL): 8
  • Evidence Score: B/10
  • Data Class: IP / Molecular Data

folder_shared Verified Assets

description
Verified Case Study
PDF • Version 1
lock
verified_user
Technical Audit
PDF • Audited
lock

Related Intelligence

article
High-Volume Claims Data Ingestion
View Outcome →
article
Generative AI for Software Engineering Productivity
View Outcome →
article
API-Integrated Gig Economy Insurance
View Outcome →
Security Architecture

The "Blind Verification" Protocol

How we verified these outcomes for A top global pharmaceutical company without exposing sensitive IP or identities.

Private
lock_person

1. Raw Evidence

Audit ID: #PRIV-519
Evidence: Direct SQL Logs
Public
public

2. Verified Asset

Outcome: Verified
Ref ID: #COI-519

Strategic Action Center

Identify your current stage and take the next step.

rocket_launch
Replicate This Success
Want similar results? Request a deployment consultation.
psychology_alt
Submit Challenge
Have a different problem? Submit your problem statement.
publish
Publish Case Study
Submit your own verified evidence.
thumb_up
Verify Impact
Audit your existing solution.